Phase II Study of Docetaxel Plus CDDP for NSCLC Stage III

National Taiwan University Hospital41 enrolled

Overview

To assess the overall response rate to docetaxel plus CDDP as neoadjuvant chemotherapy prior to surgery, followed by adjuvant docetaxel plus CDDP in chemonaive patients NSCLC Stage IIIa and IIIb.

Study Type

INTERVENTIONAL

Allocation

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

NSCLC

Interventions

Docetaxel Plus CDDPDRUG

docetaxel 36mg/m2 and cisplatin 75mg/m2

Eligibility

Sex: ALLMin age: 20 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Histologically or cytologically confirmed NSCLC, respectable NSCLC stage IIIa T1-2 N2 or or unresectable stage IIIb 2.KPS\>70% 3.Hb\>10g/dl,ANC\>2.0x109/L,Plt.\>100x109/L4.T-bil.\<1xULN,creatinine\<1xULN,creatinine clearance \>60 ml/min,GPT/GOT\<2.5xULN,ALP\<5xULN Exclusion Criteria: * 1.Brain meta.2..Prior surgery,R/T, C/t or immunotherapy for NSCLC

Locations (1)

Department of Internal Medicine, National Taiwan University Hospital

Taipei, Taiwan

Outcomes

Primary Outcomes

overall response rate

Time frame: every cycle during 2nd-6th cycles

Secondary Outcomes

resectability

Time frame: resectability after treatment

progression free survival

Time frame: progression free survival after 1 year

overall survival

Time frame: overall survival at 1 year

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.